■细小病毒,以它们对血细胞的嗜性为特征,可表现为无症状感染。凭借他们坚持血液的能力,评估健康献血者中细小病毒B19(B19V)和细小病毒4(PARV4)的流行率对于评估通过输血的潜在传播风险至关重要。强调需要全面的筛查方案。
■四百名献血者参与了这项研究,在获得知情同意后,对其血液样本进行B19V和PARV4核酸的实时PCR分析。此外,使用酶联免疫吸附测定(ELISA)对所有收集的样品进行全血细胞计数(CBC)评估以及抗B19V-IgM和抗B19V-IgG抗体滴度的测定。
■结果显示,400人中有12人(3%)对B19VDNA表现出阳性结果,而400人中有6人(1.5%)的PARV4DNA检测呈阳性。此外,400人中有8人(2%)显示抗B19VIgM阳性结果,400名个体中的306名(76.5%)显示抗B19IgG阳性结果。值得注意的是,随后通过Real-TimePCR确认了1例来自一名提供抗IgM抗体的供体的捐赠为B19VDNA阳性.在CBC的分析中,在B19V阳性供体之间观察到血小板水平的显著差异,PARV4阳性捐赠者,和B19V阴性捐赠者。
■研究表明,高危人群,缺乏可检测的B19V抗体,应该进行系统的筛查和排除。此预防措施旨在将研究队列中的潜在污染风险降至最低。尽管PARV4的发病机制和临床意义不明确。
UNASSIGNED: Parvoviruses, characterized by their tropism for blood cells, can manifest as asymptomatic infections. With their ability to persist in blood, assessing the prevalence of Parvovirus B19 (B19V) and Parvovirus 4 (PARV4) among healthy blood donors is essential for evaluating the potential transmission risks through blood transfusions, emphasizing the need for comprehensive screening protocols.
UNASSIGNED: Four hundred blood donors participated in the study, with their blood specimens subjected to Real-Time PCR analysis for B19V and PARV4 nucleic acids after obtaining informed consent. Additionally, Complete Blood Count (CBC) assessments and determination of anti-B19 V-IgM and anti-B19 V-IgG antibody titers were performed using Enzyme-Linked Immunosorbent Assay (ELISA) for all collected samples.
UNASSIGNED: The results reveal that 12 out of 400 individuals (3 %) exhibited positive results for B19V DNA, while 6 out of 400 individuals (1.5 %) tested positive for PARV4 DNA. Additionally, 8 out of 400 individuals (2 %) displayed positive results for anti-B19V IgM, and 306 out of 400 individuals (76.5 %) exhibited positive results for anti-B19 IgG. Notably, one donation from a donor presenting anti-IgM antibodies was subsequently confirmed as B19V DNA-positive through Real-Time PCR. In the analysis of CBC, a significant disparity in platelet levels was observed between B19V-positive donors, PARV4-positive donors, and B19V-negative donors.
UNASSIGNED: The study suggests that individuals at high risk, lacking detectable B19V antibodies, should undergo systematic screening and exclusion. This precaution is intended to minimize potential contamination risks within the studied cohort, despite the undefined pathogenesis and clinical implications of PARV4.